Ernexa Therapeutics Inc. (ERNA) relative valueRV
ERNA's operating margin of -1601.2% ranks in the 56th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
Kresmion ranks ERNA against its industry peers from annual SEC filings and market-price snapshots.
Against 19 Biotechnology peers
| Metric | ERNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 582K USD | 54.2K USD | 55th | 9 |
| Revenue YoY | n/a | n/a | n/a | n/a |
| Gross margin | 83.5% | 77.6% | 75th | 5 |
| Operating margin | -1601.2% | -2190.0% | 56th | 7 |
| Net margin | -2419.9% | -1721.0% | 44th | 7 |
| Return on equity | -586.6% | -120.7% | 3rd | 15 |
| P / E | n/a | n/a | n/a | n/a |
| 1 year | -93.5% | -88.1% | 35th | 12 |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2025-12-31 and 2026-06-30. Prices as of 2026-10-14. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001493152-26-010102
Peer set, 19 companies
GRI, PMCB, PCSA, EMMA, APTOF, CLDI, NCNA, HCWB, MBIO, ONCO, CVKD, GLMD, SXTP, APVO, REVB, XBIO, LNAI, JUNS, KAPA
Left out: ENLV (no annual filing), BVAXF (no annual filing), MLEC (period gap), LIMN (no annual filing), XTLB (period gap), XRTX (no annual filing).
What could not be compared
- 64 The filer did not report this line in the filing used.
- 17 The denominator is zero or negative, so the ratio has no meaning.
- 6 The price series does not reach back to the start of this window.
- 4 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
- 4 The latest close times the filed share count disagrees with the company's market cap by more than a split-sized factor, so price and the filing are not on one share basis.
- 3 The share price jumped by a stock-split ratio after the filing this figure comes from, and no later filing has restated it on the new share basis yet, so price and per-share figures may be on different bases.
- 2 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
- 2 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 2 This company's fiscal year ends more than 200 days from the subject's, so it is a different economic year.
- 2 The newest price is more than 10 days old.
- 1 Not meaningful: the prior year is zero, negative, or too small a base for a percentage to describe. Both figures are shown instead.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, the filing behind every cell, and CSV. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "ERNA relative value, Kresmion", data as of 2026-03-13, https://kresmion.com/tools/relative-value/ERNA. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/ERNA">ERNA relative value, Kresmion (Kresmion)</a>